JonesTrading analyst Soumit Roy maintained a Buy rating on IN8bio (INAB – Research Report) today and set a price target of $1.20.
Soumit Roy has given his Buy rating due to a combination of factors that highlight IN8bio’s potential in the biotechnology sector. The company is advancing its leukemia program with promising data updates expected in the second half of 2025, which could serve as significant milestones. The expansion cohort, focusing primarily on AML, is designed to mitigate risks associated with the registration trial, and early results have shown 100% relapse-free survival in a Phase 1 trial for AML patients.
Additionally, IN8bio’s financial position, with approximately $15 million in cash, is projected to support operations into 2026. Despite the capital overhang risk, the company’s strategic exploration of partnerships for its gamma-delta T cell engager program targeting CD19 could provide further development opportunities. The valuation, based on a combination of DCF, NPV, and PE methods, supports a price target of $1.20, indicating a positive outlook for the stock.
According to TipRanks, Roy is an analyst with an average return of -23.4% and a 17.37% success rate. Roy covers the Healthcare sector, focusing on stocks such as Chimerix, Day One Biopharmaceuticals, and Precision BioSciences.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $6.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com